Algiers, Algeria – A new era in diabetes treatment has begun in Algeria with the introduction of advanced insulin pens by Saidal Group, in collaboration with Novo Nordisk. This project represents a significant step towards strengthening the local production of strategic medicines.
The launch ceremony, held at Novo Nordisk’s headquarters in Boufarik, Blida, was attended by key figures including Saidal Group’s CEO, Nabila Ben Yagzer Mouloud Warth, and Novo Nordisk Algeria’s General Manager, Hamza Ben Harkat, along with other officials from both organizations.
According to a statement from Saidal Group, preparations for this project commenced in September, involving intensive technical and institutional coordination. This collaboration culminated in the signing of a memorandum of understanding, followed by a formal agreement in October. The ultimate goal is to achieve complete local production of insulin pens within Algeria.
The manufacturing process is expected to take place at Saidal’s Constantine unit, enabling the localization of this vital medication and reducing reliance on imports. This initiative aligns with Algeria’s strategy for pharmaceutical sovereignty.
Beyond manufacturing, the agreement also encompasses the gradual integration of innovative therapeutic solutions developed by Novo Nordisk. This ensures that Algerian patients have access to modern and effective treatments that meet international standards for diabetes care.
Saidal Group has experienced significant growth, with its turnover increasing from 12 billion dinars in 2023 to 24 billion dinars in 2024. Projections estimate a further increase to 35 billion dinars in 2025. This growth is attributed to the expansion of the group’s activities in biotechnological drugs, particularly for cancer, hemophilia, and diabetes, as well as the launch of product development initiatives.
This partnership will introduce new products and partnerships aimed at bolstering the nation’s pharmaceutical independence.
